直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 119484
著者
Takeuchi, Eiji National Hospital Organization Kochi Hospital
Kondo, Kensuke Tokushima University
Okano, Yoshio National Hospital Organization Kochi Hospital
Ichihara, Seiya National Hospital Organization Kochi Hospital
國重, 道大 National Hospital Organization Kochi Hospital
Kadota, Naoki National Hospital Organization Kochi Hospital
Machida, Hisanori National Hospital Organization Kochi Hospital
Hatakeyama, Nobuo National Hospital Organization Kochi Hospital
Naruse, Keishi National Hospital Organization Kochi Hospital
軒原, 浩 Tokushima University
キーワード
biomarker
immune checkpoint inhibitors
non-small cell lung cancer
predictive factor
pretreatment eosinophils
資料タイプ
学術雑誌論文
抄録
Background: The peripheral blood eosinophil count prior to treatment has potential as a predictive biomarker for a beneficial clinical response to cancer immunotherapies. Therefore, the present study investigated the impact of the eosinophil count on overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI).
Methods: We retrospectively reviewed all patients diagnosed with NSCLC and treated with ICI monotherapy between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.
Results: A total of 166 patients were included. Fifty-five patients had an eosinophil count of less than 100 cells/μL (Eo < 100). Nighty-eight patients had an eosinophil count of 100 cells/μL or more, but less than 500 cells/μL (100 ≤ Eo < 500). Thirteen patients had an eosinophil count of 500 cells/μL or more (Eo ≥500). The median OS of all lung cancer patients was 476 days. The median OS of lung cancer patients with Eo <100, 100 ≤ Eo <500, and Eo ≥500 was 339, 667, and 143 days, respectively. A Kaplan–Meier univariate analysis showed a significant difference in OS between these three groups (p < 0.001). A Cox proportional regression analysis identified 100 ≤ Eo <500 (p = 0.04), ECOG PS score ≥ 2 (p = 0.02), tumor size ≥5 cm (p = 0.02), and PD-L1 ≥ 1% (p = 0.01) as independent predictors of OS.
Conclusion: OS was significantly longer in ICI-treated NSCLC patients with a pretreatment eosinophil count of 100 ≤ Eo <500 than in the other patients and, thus, has potential as a new predictive biomarker.
掲載誌名
Thoracic Cancer
ISSN
17597706
17597714
出版者
China Lung Oncology Group|John Wiley & Sons Australia
14
30
開始ページ
3042
終了ページ
3050
発行日
2023-09-05
権利情報
This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系
病院